🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "major milestone" in the battle against increasingly resistant strains of the bacteria, according to researchers.

A Worldwide Public Health Issue

Cases of gonorrhoea are escalating around the world, with estimates suggesting over 82 million instances per year. Particularly high rates are observed in Africa and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have reached a record high, while figures across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary advancement in the context of growing infection rates, the spread of superbugs and the highly restricted available drugs currently available.”

Public health authorities are increasingly worried about the increase in treatment-resistant strains. The global health body has designated it as a "high-priority threat". A tracking program showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Treatment Options Gain Authorization

One new antibiotic, marketed under the name a brand name, was approved by the American regulatory agency in mid-December for combating gonorrhoea. This STI can lead to serious health problems, including infertility. Researchers anticipate that targeted use of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This medication, which is additionally indicated for UTIs, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Development Model

This new treatment emerged from a innovative non-profit model for antibiotic development. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to develop it.

“This authorization signifies a huge turning point in the management of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Testing Results and Worldwide Availability

As per findings detailed in a major medical journal, zoliflodacin eradicated the vast majority of uncomplicated infections. This places it at an comparable level with the current standard treatment, which involves a dual-drug approach. The research involved nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the ability to license and sell the drug in many low-income and middle-income countries.

Doctors treating patients have voiced positive views. The availability of a one-pill regimen such as this is seen as a "critical tool" for gonorrhoea control. This is deemed crucial to alleviate the strain of the illness for people and to stop the proliferation of untreatable gonorrhoea worldwide.